Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2

Autores
Raiden, Silvina Claudia; Geffner, Jorge Raúl
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The new wave of COVID-19 in Europe and the emergence of a new variant of concern called Omicron, first detected in southern African countries then subsequently in Europe, Asia and America, demands once again rapid and equitable access to vaccines especially in low-income countries. In stark contrast with a large number of published papers related to the vaccines BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna/ NIAID), and (ChAdOx1-S Astrazeneca/ University of Oxford), very few reports have been published referring to the Sputnik-V vaccine (Gamaleya National Center of Epidemiology and Microbiology). Sputnik-V is being used in more than 70 countries, mainly in South America, Africa and Asia, but has not been yet approved for emergency use by the World Health Organization. In The Lancet Regional Health−Americas, Chahla RE and colleagues report a long-term analysis of the antibody response in 602 health workers from Argentina vaccinated by Sputnik V between December 2020 and July 2021. Confirming previous results published in phase I/II studies,1 the authors report seroconversion levels of 97% at 7 days after the application of the second dose. Follow-up of vaccinated individuals showed that the serum levels of IgG anti-RBD antibodies remain detectable in 94% of individuals at 90 days after vaccination, decreasing this percentage to 31% at 180 days after vaccination
Fil: Raiden, Silvina Claudia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños Pedro Elizalde (ex Casa Cuna); Argentina
Fil: Geffner, Jorge Raúl. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Materia
ANTIBODY RESPONSES
SPUTNIK V VACCINE
COVID-19
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/161413
Acceder
id CONICETDig_616ba3ebfd9877662404a1589b668708
oai_identifier_str oai:ri.conicet.gov.ar:11336/161413
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2Raiden, Silvina ClaudiaGeffner, Jorge RaúlANTIBODY RESPONSESSPUTNIK V VACCINECOVID-19https://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3The new wave of COVID-19 in Europe and the emergence of a new variant of concern called Omicron, first detected in southern African countries then subsequently in Europe, Asia and America, demands once again rapid and equitable access to vaccines especially in low-income countries. In stark contrast with a large number of published papers related to the vaccines BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna/ NIAID), and (ChAdOx1-S Astrazeneca/ University of Oxford), very few reports have been published referring to the Sputnik-V vaccine (Gamaleya National Center of Epidemiology and Microbiology). Sputnik-V is being used in more than 70 countries, mainly in South America, Africa and Asia, but has not been yet approved for emergency use by the World Health Organization. In The Lancet Regional Health−Americas, Chahla RE and colleagues report a long-term analysis of the antibody response in 602 health workers from Argentina vaccinated by Sputnik V between December 2020 and July 2021. Confirming previous results published in phase I/II studies,1 the authors report seroconversion levels of 97% at 7 days after the application of the second dose. Follow-up of vaccinated individuals showed that the serum levels of IgG anti-RBD antibodies remain detectable in 94% of individuals at 90 days after vaccination, decreasing this percentage to 31% at 180 days after vaccinationFil: Raiden, Silvina Claudia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños Pedro Elizalde (ex Casa Cuna); ArgentinaFil: Geffner, Jorge Raúl. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaElsevier2022-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/161413Raiden, Silvina Claudia; Geffner, Jorge Raúl; Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2; Elsevier; The Lancet Regional Health - Americas; 6; 100172; 2-2022; 1-22667-193XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.thelancet.com/journals/lanam/article/PIIS2667-193X2100168-X/fulltext#:~:text=Follow%2Dup%20of%20vaccinated%20individuals,at%20180%20days%20after%20vaccination.info:eu-repo/semantics/altIdentifier/doi/10.1016/j.lana.2021.100172info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S2667193X2100168Xinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:47:18Zoai:ri.conicet.gov.ar:11336/161413instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:47:18.609CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2
title Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2
spellingShingle Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2
Raiden, Silvina Claudia
ANTIBODY RESPONSES
SPUTNIK V VACCINE
COVID-19
title_short Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2
title_full Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2
title_fullStr Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2
title_full_unstemmed Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2
title_sort Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2
dc.creator.none.fl_str_mv Raiden, Silvina Claudia
Geffner, Jorge Raúl
author Raiden, Silvina Claudia
author_facet Raiden, Silvina Claudia
Geffner, Jorge Raúl
author_role author
author2 Geffner, Jorge Raúl
author2_role author
dc.subject.none.fl_str_mv ANTIBODY RESPONSES
SPUTNIK V VACCINE
COVID-19
topic ANTIBODY RESPONSES
SPUTNIK V VACCINE
COVID-19
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The new wave of COVID-19 in Europe and the emergence of a new variant of concern called Omicron, first detected in southern African countries then subsequently in Europe, Asia and America, demands once again rapid and equitable access to vaccines especially in low-income countries. In stark contrast with a large number of published papers related to the vaccines BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna/ NIAID), and (ChAdOx1-S Astrazeneca/ University of Oxford), very few reports have been published referring to the Sputnik-V vaccine (Gamaleya National Center of Epidemiology and Microbiology). Sputnik-V is being used in more than 70 countries, mainly in South America, Africa and Asia, but has not been yet approved for emergency use by the World Health Organization. In The Lancet Regional Health−Americas, Chahla RE and colleagues report a long-term analysis of the antibody response in 602 health workers from Argentina vaccinated by Sputnik V between December 2020 and July 2021. Confirming previous results published in phase I/II studies,1 the authors report seroconversion levels of 97% at 7 days after the application of the second dose. Follow-up of vaccinated individuals showed that the serum levels of IgG anti-RBD antibodies remain detectable in 94% of individuals at 90 days after vaccination, decreasing this percentage to 31% at 180 days after vaccination
Fil: Raiden, Silvina Claudia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños Pedro Elizalde (ex Casa Cuna); Argentina
Fil: Geffner, Jorge Raúl. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
description The new wave of COVID-19 in Europe and the emergence of a new variant of concern called Omicron, first detected in southern African countries then subsequently in Europe, Asia and America, demands once again rapid and equitable access to vaccines especially in low-income countries. In stark contrast with a large number of published papers related to the vaccines BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna/ NIAID), and (ChAdOx1-S Astrazeneca/ University of Oxford), very few reports have been published referring to the Sputnik-V vaccine (Gamaleya National Center of Epidemiology and Microbiology). Sputnik-V is being used in more than 70 countries, mainly in South America, Africa and Asia, but has not been yet approved for emergency use by the World Health Organization. In The Lancet Regional Health−Americas, Chahla RE and colleagues report a long-term analysis of the antibody response in 602 health workers from Argentina vaccinated by Sputnik V between December 2020 and July 2021. Confirming previous results published in phase I/II studies,1 the authors report seroconversion levels of 97% at 7 days after the application of the second dose. Follow-up of vaccinated individuals showed that the serum levels of IgG anti-RBD antibodies remain detectable in 94% of individuals at 90 days after vaccination, decreasing this percentage to 31% at 180 days after vaccination
publishDate 2022
dc.date.none.fl_str_mv 2022-02
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/161413
Raiden, Silvina Claudia; Geffner, Jorge Raúl; Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2; Elsevier; The Lancet Regional Health - Americas; 6; 100172; 2-2022; 1-2
2667-193X
CONICET Digital
CONICET
url http://hdl.handle.net/11336/161413
identifier_str_mv Raiden, Silvina Claudia; Geffner, Jorge Raúl; Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2; Elsevier; The Lancet Regional Health - Americas; 6; 100172; 2-2022; 1-2
2667-193X
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.thelancet.com/journals/lanam/article/PIIS2667-193X2100168-X/fulltext#:~:text=Follow%2Dup%20of%20vaccinated%20individuals,at%20180%20days%20after%20vaccination.
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.lana.2021.100172
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S2667193X2100168X
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613474570731520
score 13.069144

Publicaciones similares